(Credit: NIH; Thinkstock)
Even now, it looks as if the number of U.S. deaths caused by COVID-19 may not be big enough to do much to the typical publicly traded U.S. life and annuity issuer's 2020 earnings.
Ryan Krueger, a securities analyst at Keefe, Bruyette & Woods Inc., makes that case in a new analysis of COVID-19 mortality scenarios.
(Related: Humana Tells Investors About COVID-19 Risks)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the COVID-19 disease, can kill people by causing pneumonia, heart inflammation and kidney failure.
The U.S. Centers for Disease Control and Prevention reported Monday that it had recorded 140,904 cases of COVID-19 that were confirmed by state, municipal or federal testing laboratories, and 2,405 COVID-19-related deaths.
Many cities and states, including California and New York, have shut down schools, restaurants and hair salons, and encouraged residents to stay at home, in an effort to slow the spread of SARS-CoV-2.
Krueger did not include the economic impact of COVID-19 "shelter in place" and "stay at home" campaigns in his new analysis; he focused solely on mortality.
The General Analysis
In the analysis, which is published behind a paywall, Krueger presents a chart that shows how the deadliness of the 1918 Spanish flu pandemic compares with the deadliness of other famous pandemics, and tables that show what the excess death rate per 1,000 insured lives might be like in a range of SARS-CoV-2 infection rate and fatality rate scenarios.
At this point, he says, his base assumption is that the current pandemic will end up being more like the terrible "Asian flu" pandemic of 1957, rather than like the catastrophic 1918 pandemic.
He assumes in his own base scenario that about 20% of U.S. residents will end up having COVID-19, and that the death rate for people who get COVID-19 will be about 0.5%, or four times the death rate for ordinary flu.
Under those assumptions, COVID-19 could cause about 330,000 deaths.
